Batimastat

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Batimastat
Batimastat skeletal.svg
Systematic (IUPAC) name
(2R,3S)-N4-Hydroxy-2-isobutyl-N1-[(2S)-1-(methylamino)-1-oxo-3-phenyl-2-propanyl]-3-[(2-thienylsulfanyl)methyl]succinamide
Clinical data
Pregnancy cat. N/A
Legal status Never marketed
Routes Injection into pleural space or abdomen
Identifiers
CAS number 130370-60-4
ATC code None
PubChem CID 5362422
DrugBank DB03880
ChemSpider 4515033
KEGG D03061
ChEMBL CHEMBL279786
Chemical data
Formula C23H31N3O4S2 
Mol. mass 477.64 g/mol

Batimastat (INN/USAN, codenamed BB-94) is an anticancer drug that belongs to the family of drugs called angiogenesis inhibitors. It acts as a matrix metalloproteinase inhibitor (MMPI) by mimicking natural MMPI peptides.

Batimastat was the first MMPI that went into clinical trials. First results of a Phase I trial appeared in 1994. The drug reached Phase III but was never marketed; mainly because it couldn't be administered orally (as opposed to the newer and chemically similar MMPI marimastat), and injection into the peritoneum caused peritonitis.[1]

References[edit]

  1. ^ Rothenberg, M. L.; Nelson, A. R.; Hande, K. R. (1999). "New Drugs on the Horizon: Matrix Metalloproteinase Inhibitors". Stem Cells 17 (4): 237–240. doi:10.1002/stem.170237. PMID 10437989.  edit

 This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".